Bank of America’s Sage Therapeutics SAGE Stock Holding History

Bank of America’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,000	Closed	-$1.41M	–	7922
2023 Q2	$1.41M	Buy	+30,000	New	+$1.49M	﹤0.01%	4517
2020 Q1	–	Sell	-22,200	Closed	-$1.6M	–	7192
2019 Q4	$1.6M	Buy	22,200 +11,100	+100%	+$1.37M	﹤0.01%	4182
2019 Q3	$1.56M	Buy	+11,100	New	+$1.86M	﹤0.01%	4238
2019 Q1	–	Sell	-5,000	Closed	-$479K	–	7374
2018 Q4	$479K	Buy	+5,000	New	+$572K	﹤0.01%	4959
2018 Q1	–	Sell	-214,600	Closed	-$35.3M	–	7311
2017 Q4	$35.3M	Buy	214,600 +112,400	+110%	+$10.9M	0.01%	1360
2017 Q3	$6.37M	Buy	102,200 +97,400	+2,029%	+$7.65M	﹤0.01%	2951
2017 Q2	$382K	Buy	+4,800	New	+$347K	﹤0.01%	5031

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bank of America's SAGE Position: Q3 2025 in Review

Bank of America sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 145,799 shares — an estimated $1.33M sold.

Bank of America first reported a position in SAGE in Q4 2014 and held it in 43 quarters. The position peaked at $44.7M in Q1 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Bank of America reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Bank of America sold 145,799 Sage Therapeutics shares in Q3 2025, an estimated $1.33M.
Bank of America first reported a position in Sage Therapeutics in Q4 2014 and held it in 43 quarters.
Bank of America's Sage Therapeutics position peaked at $44.7M in Q1 2019.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.